Submit

Login Login

Register Register

Home / Journals / OR / Online First / doi:10.32604/or.2026.071213
Journal Menu
Special Issues
Table of Content

All issues

Online First

2026

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

Past Issues

Open Access

CASE REPORT

Case Report: A Case of Neuroendocrine Carcinoma of the Endometrium with Deficient DNA Mismatch Repair Had Achieved Clinical Complete Response after Combination Therapy

Xie Ding1,2,3,#, Xinfeng Liu4,#, Cheng Dai5, Xiaoxiao Wang1,2,3, Zhaopeng Zheng2,3,*
1 The Second Clinical College, Zunyi Medical University, Zunyi, China
2 Department of Oncology, The People’s Hospital of QianNan, Duyun, China
3 Department of Oncology, Guizhou Provincial People’s Hospital, Guiyang, China
4 Department of Radiology, Guizhou Provincial People’s Hospital, Guiyang, China
5 Department of Gynecology, Guizhou Provincial People’s Hospital, Guiyang, China
* Corresponding Author: Zhaopeng Zheng. Email: email
# These authors contributed equally to this work as the first author

Oncology Research https://doi.org/10.32604/or.2026.071213

Received 02 August 2025; Accepted 03 February 2026; Published online 06 March 2026

Abstract

Background: Immunotherapy has markedly reshaped the therapeutic landscape for patients with postoperative progression and metastasis. As a programmed death-1 (PD-1) inhibitor, camrelizumab has been proven to exhibit both efficacy and safety in the treatment of advanced dMMR solid tumors. Case Description: A 58-year-old female patient with neuroendocrine carcinoma of the endometrium (NECE) who was treated with camrelizumab coupled with chemotherapy, subsequent maintenance monotherapy with camrelizumab, and adjuvant pelvic local radiotherapy. Up to December 2024, the patient has survived 28 months since treatment, with 26 months free from disease progression, and the assessment indicated a status of clinical complete response (cCR). Conclusion: The combined regimen achieves notable efficacy and is free of unexpected adverse effects, with only a radiotherapy-related pelvic insufficiency fracture (PIF) report.

Keywords

Neuroendocrine carcinoma of the endometrium (NECE); DNA mismatch repair deficiency (dMMR); programmed death-1 (PD-1) inhibitor; camrelizumab; combination chemotherapy; adjuvant radiotherapy; case report

  • 109

    View

  • 18

    Download

  • 0

    Like

Related articles
Copyright© 2026 Tech Science Press
© 1997-2026 TSP (Henderson, USA) unless otherwise stated

Share Link